Aligos Therapeutics submits response to Janssen Biopharma

Aligos Therapeutics submits response to Janssen Biopharma


SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in Virus – and liver disease, filed an answer to Janssen Biopharma’s lawsuit and counterclaims against Janssen Biopharma in California State Superior Court for the County of San Mateo.

Specifically, the response to Janssen’s complaint identifies the Aligos co-founders’ decades-old publicly available information (published patents and scientific literature), previous work experience, publications and patents at other oligonucleotide companies in relation to the initial discovery of oligonucleotides (ASO and siRNA). hepatitis B virus (HBV), as well as the licenses Aligos has received from universities and biotechnology companies – all of which have been used as the basis for Aligos’ HBV portfolio. The reply further elaborates and documents that all work was carried out by Aligos employees after they left Janssen Biopharma.

The counterclaims against Janssen accuse Janssen of unfair competition and promissory note fraud. Aligos co-founders Lawrence M. Blatt, Ph.D., MBA, and Leonid Beigelman, Ph.D. joined Aligos in filing the counterclaims. That answer and counterclaims can be found under the respective hyperlinks.

“I encourage anyone interested in this matter to read our response and counterclaims,” ??said Lawrence M. Blatt, Ph.D., MBA, CEO, Chairman and Co-Founder of Aligos. “The facts are on Aligos’ side and we will continue to defend ourselves against Janssen’s unfounded allegations.”

About Aligos

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 with the goal of becoming a global leader in the treatment of viral infections and liver diseases. Aligos is focused on discovering and developing targeted antiviral therapies for chronic hepatitis B (CHB) and…

Continue to read on GlobeNewswire

More to explorer

Understanding Key Factors in Accidents

Pedestrian Safety Statistics Pedestrian safety is an urgent concern worldwide, with over 1.3 million people dying in traffic accidents annually. Pedestrians account